Phenibut
Viewing r1 — Apr 26, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Phenibut (4-amino-3-phenylbutanoic acid) is a synthetic depressant and anxiolytic of the gabapentinoid class. It is structurally related to baclofen, differing by a single chlorine atom on the phenyl ring.[1] Phenibut is a GABA-B receptor agonist and α₂-δ calcium channel ligand, producing its effects by reducing neuronal excitability through two independent inhibitory mechanisms.[2][3]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
baclofen, gabapentin, pregabalin +1 morebaclofen, gabapentin, pregabalin, benzodiazepines show less
Synthesized in the early 1960s at the A.I. Herzen Leningrad Pedagogical Institute, phenibut was developed as a GABA structural analog capable of crossing the blood-brain barrier.[4] It entered Soviet clinical practice as an anxiolytic and was included in cosmonaut medical kits for its ability to reduce anxiety without impairing cognition.[4] It remains a prescription medicine in Russia and several former Soviet states but is unregulated or increasingly restricted across Western countries, where it circulates primarily through online supplement markets.[5]
Subjective effects include anxiolysis, euphoria, sociability enhancement, and sedation.[6] The experience is characterized by a warm, socially lubricating calm — less impairing than alcohol, more euphoric than baclofen — underscored by an exceptionally slow onset that tempts premature redosing. Motor impairment, somnolence, and cognitive dulling are common unsought effects at higher doses.
Phenibut produces rapid physical dependence, with tolerance developing within days of continuous use,[7] though no confirmed fatalities from monotherapy appear in Western literature.[8] The primary danger is escalation: doses commonly climb from the therapeutic range into multi-gram territory, and abrupt cessation can trigger withdrawal severe enough to include delirium, hallucinations, and seizures.[9][10] No Western clinical trials have been conducted; the English-language evidence base rests on case reports, poison center surveillance, and systematic reviews.[5]
History[edit]
Discovery
Phenibut — originally named "phenigamma" — was first synthesized by Professor Vsevolod Perekalin and his team at the Department of Organic Chemistry at the A.I. Herzen Leningrad Pedagogical Institute in the early 1960s.[4][5] The goal was to create a GABA structural analog that could cross the blood-brain barrier — which GABA itself cannot — and produce anxiolysis with less sedation than existing tranquilizers.[11] Adding a phenyl group to the GABA backbone provided the lipophilicity needed for CNS penetration while preserving GABAergic activity.[6]
Clinical adoption and cosmonaut use
Phenibut entered clinical practice in Russia during the 1960s and was eventually registered under brand names including Noofen in Russia, Ukraine, Belarus, Georgia, and Latvia.[6] Indications in these countries include insomnia, anxiety, PTSD, vestibular disorders, and pre-operative anxiolysis.[6] Its inclusion in Soviet cosmonaut medical kits cemented its reputation as a performance-compatible anxiolytic — unlike benzodiazepines, it could lower stress without degrading cognitive or operational function during spaceflight.[4]
Western emergence and regulation
The first English-language pharmacological overview appeared in 2001,[6] and case reports of dependence began surfacing in 2013.[9] Phenibut's penetration of online supplement markets in North America and Europe triggered a wave of adverse event reports: US poison center calls rose substantially between 2009 and 2019.[12][13] Regulatory responses have included WHO surveillance (2017),[14] Australia's Schedule 9 classification (2018),[15] FDA warning letters and a determination that phenibut is not a dietary ingredient (2019–2023),[16] and state-level scheduling in the US.[17]
The name "phenibut" derives from its chemical structure: phenyl + butanoic acid, with the intermediate syllable reflecting its GABA (γ-aminobutyric acid) parentage. In Russian-language pharmacology it is categorized as a "nootropic" — a term carrying broader clinical connotations in post-Soviet medicine than in Western usage, where nootropic typically implies cognitive enhancement. Online communities frequently describe phenibut as a "social lubricant" or "confidence pill," framing it against alcohol as an alternative anxiolytic for social situations — a positioning that obscures its dependence potential.
Chemistry[edit]
Structural class
Phenibut (4-amino-3-phenylbutanoic acid) is a synthetic phenyl-substituted derivative of GABA (GABA), belonging to the β-phenyl-GABA structural class.[6] The addition of a phenyl group at the β-carbon gives the molecule enough lipophilicity to cross the blood-brain barrier — a barrier that unsubstituted GABA cannot penetrate.[6] Baclofen is the nearest structural relative, differing only by a para-chlorine on the phenyl ring.[6] Gabapentin and pregabalin, while structurally distinct, share phenibut's α₂-δ calcium channel binding activity and are grouped with it as gabapentinoids.[18]
Molecular properties
| Molecular formula | C₁₀H₁₃NO₂ |
| Molecular weight | 179.22 g/mol |
Stereochemistry
Phenibut has one chirality center at C3 and is used clinically as a racemic mixture.[2] The enantiomers differ sharply in activity: the R-enantiomer is the active species at GABA-B receptors, while the S-enantiomer is inactive at this target.[2] Both enantiomers bind α₂-δ calcium channel subunits, with R-phenibut showing modestly higher affinity.[3]
Physical properties
Phenibut is a white crystalline solid with limited water solubility.[19] No published LogP values were identified, though the phenyl group's contribution to lipophilicity relative to unsubstituted GABA is consistently described as the structural basis for blood-brain barrier penetration.[6]
Pharmacology[edit]
Mechanism of action
Phenibut acts on two primary molecular targets. The first is the GABA-B receptor, where it functions as a low-potency agonist — roughly 30 times weaker than baclofen.[1] GABA-B activation triggers downstream neuronal inhibition: potassium channels open, calcium channels close, and overall excitatory signaling decreases.[20] The R-enantiomer is the active form at this target; the S-enantiomer shows no GABA-B activity.[2]
The second target is the α₂-δ subunit of voltage-dependent calcium channels — the same binding site used by gabapentin and pregabalin.[3][18] Phenibut binds α₂-δ with roughly four times greater affinity than it binds GABA-B.[3] In animal pain models, the analgesic effects of R-phenibut were mediated entirely through α₂-δ, not GABA-B.[3]
Additional minor targets include GABA-A receptors,[6][13] dopamine receptors,[6] and antagonism of β-phenethylamine, a trace amine implicated in anxiety.[6][11] Phenibut does not bind GHB receptors.[1]
Pharmacokinetics
Oral bioavailability is approximately 65%.[8] Peak plasma levels are reached 3–4 hours after ingestion[8] — an unusually slow onset that is directly responsible for many accidental overdoses through premature redosing. The half-life after a single 250 mg dose is 5.3–5.6 hours,[1][8] though subjective effects persist well beyond this window.
Only about 0.1% of an oral dose crosses the blood-brain barrier — a small fraction, but sufficient for CNS effects thanks to the phenyl group's lipophilicity.[6][1] Approximately 63–65% of a dose is excreted unchanged in urine.[8]
Metabolism data are conflicting: Soviet-era animal studies reported no biotransformation, while current Russian manufacturer data claims up to 95% hepatic metabolism.[8] No specific liver enzymes involved in phenibut metabolism have been identified.safety citation needed Protein binding, volume of distribution, and clearance have not been established in published literature.
Neuroscience[edit]
Where it acts
Phenibut's CNS effects arise from the convergence of two inhibitory mechanisms. GABA-B activation suppresses excitatory signaling in anxiety-relevant circuits — particularly amygdala, prefrontal cortex, and hippocampal networks — by opening potassium channels and closing calcium channels.[20] Simultaneously, α₂-δ calcium channel binding reduces neurotransmitter release through an independent pathway, producing pain suppression in spinal and central pain circuits and likely contributing to the anxiolytic and anticonvulsant effects shared with gabapentin and pregabalin.[3]
Additional dopaminergic and trace amine antagonist activity may underlie the euphoria and motivation enhancement reported at lower doses.[6] Phenibut's antagonism of β-phenethylamine represents a third anxiolytic mechanism independent of both GABA-B and α₂-δ.[6][11]
Why it matters
Phenibut's dual-mechanism inhibition — GABA-B agonism plus α₂-δ calcium channel reduction — shifts the brain's excitatory/inhibitory balance toward inhibition more comprehensively than single-target agents. This may explain why its subjective character is described as qualitatively distinct from both pure GABA-B agonists like baclofen and pure gabapentinoids like gabapentin.
This dual mechanism also explains the severity of withdrawal. Chronic use triggers compensatory upregulation of excitatory systems across both pathways; abrupt cessation creates a dual-deficit state producing rebound effect hyperexcitability — delirium, seizures, psychosis — that exceeds what either mechanism alone would generate.[5]
The relative contribution of GABA-B versus α₂-δ to phenibut's anxiolytic effect in humans remains unresolved — blocking studies that could isolate each target have not been conducted. The dopaminergic activity reported in early studies[6] lacks characterization: receptor subtype, binding affinity, and whether the effect is direct or indirect are all unknown.
Subjective Effects[edit]
Phenibut's experiential character reflects its dual mechanism — GABA-B agonism and α₂-δ calcium channel modulation — producing a profile that users consistently describe as warmer and more sociable than either mechanism alone would predict. At lower doses, functional anxiolysis dominates: social ease, mild confidence, and a subtle sense of well-being without overt intoxication. As dose increases, the experience tilts toward sedation, euphoria, and eventually motor impairment. Set and setting exert substantial influence — the same dose that supports a focused work session may produce overt sedation and euphoria in a relaxed social environment.
The closest experiential comparisons are to higher-dose gabapentin and moderate-dose alcohol, though phenibut's anxiolysis is typically reported as cleaner and longer-lasting than either. Relative to baclofen, phenibut produces more noticeable euphoria and sociability at comparable anxiolytic doses, likely reflecting its additional α₂-δ and dopaminergic activity.
Effect Grid
At common doses (1000–2000 mg oral), the full anxiolytic and euphoriant profile emerges. Anxiety suppression is pronounced — social situations that would normally produce apprehension feel manageable or enjoyable. Euphoria ranges from a sustained warm contentment to a more overt emotional elevation. Sociability enhancement is marked, with increased empathy and desire for conversation.
Sedation becomes dose-dependent and noticeable, particularly at the upper end. Muscle relaxation is appreciable. Motor control may show subtle impairment — slight unsteadiness or reduced coordination. Sleep quality is typically enhanced if dosing allows effects to extend into the sleep window.
Functional impairment is moderate: complex tasks remain possible but reaction time and fine motor control are diminished. The full experience lasts 10–16 hours including residual effects, representing a significant time commitment.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Vestibular distortion · Visual acuity suppression · Visual haze / noise · Visual processing suppression · Internal hallucinations
Internal hallucinations
Dizziness · Bodily heaviness · Insomnia · Physical fatigue · Tactile euphoria · Sexual arousal enhancement · Headache · Nausea · Body high · Brain zaps · Dry mouth · Sexual arousal suppression · Excessive sweating · Diarrhea · Dehydration sensation · Muscle tension · Pupil dilation · Temperature dysregulation · Heart rate perception changes · Nystagmus (eye wobbles) · Restlessness · Spontaneous body sensations · Stimulation · Tingling / electric sensations · Trembling · Appetite enhancement · Yawning · Increased urination · Abnormal heartbeat · Involuntary body movements · Vomiting
Physical fatigue · Tactile euphoria · Sexual arousal enhancement · Headache · Nausea · Body high · Brain zaps · Dry mouth · Sexual arousal suppression · Excessive sweating · Diarrhea · Dehydration sensation · Muscle tension · Pupil dilation · Heart rate perception changes · Nystagmus (eye wobbles) · Restlessness · Spontaneous body sensations · Stimulation · Tingling / electric sensations · Trembling · Appetite enhancement · Yawning · Increased urination · Abnormal heartbeat · Involuntary body movements · Vomiting
Analysis suppression · Thought deceleration · Cognitive dysphoria · Focus suppression · Information processing suppression · Memory suppression · Motivation enhancement · Focus enhancement · Confusion · Delusions of sobriety · Language suppression · Memory fragmentation · Thought disorganization · Amnesia · Delirium
Focus suppression · Information processing suppression · Memory suppression · Motivation enhancement · Focus enhancement · Confusion · Language suppression · Memory fragmentation · Thought disorganization · Amnesia · Delirium
Irritability · Empathy enhancement · Anhedonia · Emotional enhancement · Emotional lability · Emotional suppression
Emotional lability · Emotional suppression
Communication enhancement · Depersonalization · Communication suppression · Ego inflation · Sociability suppression · Derealization
Sociability suppression · Derealization
Timeline
First alerts emerge gradually — a subtle lightening of mood or faint reduction in baseline anxiety. The slow onset reflects phenibut's limited water solubility and 3–4 hour Tmax.
Anxiolysis becomes clearly perceptible. Social ease increases, mild euphoria surfaces, and muscle tension begins to release. Effects build slowly enough that the transition from onset to come-up is often imperceptible.
Maximum anxiolysis, euphoria, and sociability. Sedation is dose-dependent — mild warmth at common doses, pronounced drowsiness at strong doses. Muscle relaxation and subtle motor impairment are present.
Effects sustain at reduced intensity. Anxiolysis remains but euphoria fades. Sedation may increase as stimulating components recede.
Gradual return toward baseline. Residual sedation and muscle relaxation persist. Mood remains mildly elevated.
Residual calmness, mild fatigue, or slight cognitive blunting may persist for 6–24 hours after subjective effects resolve. Some users report improved sleep quality on the following night.
⚠ Do not drive or operate heavy machinery until at least 24 hours after dosing, as residual sedation and impaired reaction time may persist beyond the subjective experience.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- High
- Withdrawal
- Severe
- Tolerance buildup
- rapid
- Tolerance reset
- —
- Physical
- High
- Psychological
- High
- Compulsive redosing
- Moderate
- Dose escalation
- High
- Cross-tol.
- baclofen · gabapentin · pregabalin
Toxicity
Acute toxicity
No published LD₅₀ data for phenibut exist in English-language literature.safety citation needed The maximum reported surviving single oral dose is 100 g in a monotherapy case, which produced neither respiratory depression nor signs of severe intoxication.[8] No confirmed fatalities from phenibut alone appear in published Western literature as of 2024.[8]
The risk profile changes dramatically in polysubstance contexts: approximately 50% of US intoxication cases required intubation, primarily when phenibut was combined with opioids, benzodiazepines, or alcohol.[8] Overdose follows a CNS depression spectrum — sedation, unsteady movement, muscle weakness, progressing to unresponsiveness and coma. Paradoxical stimulation, including agitation and acute psychosis, has also been reported.[14][5]
Detection
Standard urine and blood drug screens do not detect phenibut.[5][11] Identification requires specialized laboratory testing that most emergency departments do not have readily available. This means clinicians may not recognize phenibut involvement in cases of unexplained CNS depression.
Psychological risks
At therapeutic and moderate recreational doses, acute psychological distress is uncommon. The psychological risk profile is dominated by dependence rather than acute toxicity.
At high doses or during withdrawal, reported effects include acute psychosis,[14] visual and auditory hallucinations,[10][5] and delirium.[10]
Compulsive use patterns are common: 73% of patients presenting with withdrawal had prior substance use disorder histories, and 60% had pre-existing anxiety or depression — suggesting self-medication as a primary driver of escalation.[21]
Tolerance and dependence
Tolerance develops within days of daily use.[7][9] The mechanism is presumed to involve GABA-B downregulation, analogous to baclofen tolerance, though phenibut-specific studies have not been published.
Phenibut produces both physical and psychological dependence.[9][22][7] Dose escalation is characteristic: the mean dose among patients presenting with withdrawal was 13.6 g/day (range 1.5–28.5 g/day), representing 7–50× escalation from the therapeutic range.[21]
Withdrawal can begin within 3–4 hours of the last dose in heavily dependent individuals.[9] Mild-to-moderate symptoms include anxiety, agitation, tremors, insomnia, nausea, rapid heart rate, and cognitive deficits.[23][21] Severe symptoms include delirium, hallucinations, psychosis, and seizures.[10][5] Acute withdrawal typically resolves over 1–2 weeks; after prolonged heavy use, symptoms can persist for up to 6 months.[1]
No standardized withdrawal treatment protocol exists.[5] Current medical approaches include baclofen taper (GABA-B substitution),[9] benzodiazepines for acute agitation and seizure prevention, phenobarbital when seizure risk is elevated,[22][5] and ancillary agents such as gabapentin, pregabalin, or dexmedetomidine.[5] Seizures have been reported even during treatment with baclofen alone.[24]
Cross-tolerance with GABA-B agonists (baclofen) is established; cross-tolerance with benzodiazepines (GABA-A) is clinically observed but less well defined.[13]
Drug interactions
No controlled interaction studies have been published — all data derive from mechanism-based inference and case reports.safety citation needed
The dominant risk is additive CNS and respiratory depression when combined with other depressants. Alcohol co-use extends and worsens withdrawal.[25] Opioids produce additive respiratory depression through converging inhibitory pathways.[13][5] Benzodiazepines add GABA-A depression on top of phenibut's GABA-B effects, and combined dependence produces a more complex withdrawal syndrome.[26] GHB/GBL, barbiturates, and muscle relaxants carry additive risk through overlapping CNS depression.
Phenibut is largely excreted unchanged in urine (~63–65%),[8] suggesting limited potential for liver-enzyme-mediated interactions. However, the absence of data on which liver enzymes process phenibut prevents confident assessment.
Contraindications
Polysubstance use with CNS depressants is the highest-risk context. The majority of serious intoxications involve co-ingestion of opioids, benzodiazepines, or alcohol.[8][5]
Breathing difficulties: Phenibut may precipitate respiratory failure in individuals with pre-existing respiratory disease or sleep apnea.[5][10]
History of substance use disorder: 73% of withdrawal cases had prior substance use disorder,[21] indicating elevated vulnerability.
Pre-existing anxiety or depression: 60% of withdrawal cases had comorbid anxiety or depression,[21] suggesting a self-medication pathway to dependence.
Daily or frequent use: Tolerance develops within days, leading to dose escalation and physical dependence.[7]
Pregnancy and lactation: No human data exist on reproductive safety or neonatal withdrawal.safety citation needed
Harm Reduction[edit]
Forms & Identification
Phenibut is most commonly encountered as a white crystalline powder (free acid or hydrochloride salt) or in capsules. Powder forms present a particular challenge: batch potency can vary, and the compound's appearance is indistinguishable from many other white powders. An analytical scale accurate to the milligram is essential for powder dosing — volumetric scooping is unreliable given that density varies between batches and salt forms.
No widely available reagent test reliably identifies phenibut. Verification of product identity typically requires sending a sample to a drug checking service that uses techniques such as FTIR or GC-MS.
Guidelines
- Weigh doses with a milligram-accurate scale. Do not estimate by volume.
- Start at the lowest effective dose and wait a full 4–5 hours before considering any additional intake — the slow onset is not a sign of underdosing.
- Avoid daily use. Tolerance develops within days, and the path from daily dosing to physical dependence is rapid.
- Do not combine with alcohol, opioids, benzodiazepines, or other CNS depressants.
- Stay hydrated and eat before dosing — phenibut on an empty stomach may produce nausea.
- Inform a trusted person of what you have taken and when, especially if using alone.
- Keep a written log of use frequency and dose amounts. Escalation often occurs gradually and goes unnoticed without records.
Set & Setting
Phenibut's exceptionally slow onset — 3–4 hours to peak — is the single most practically important feature for risk management. The temptation to redose before effects have fully developed is the most common driver of accidental overdose. A calm, familiar environment with a trusted companion reduces both physical and psychological risk, particularly at higher doses where sedation and motor impairment can escalate rapidly.
Aftercare & integration. Post-experience recovery from a single use is typically straightforward — mild fatigue, grogginess, or low mood the following day are common. Adequate sleep, hydration, and light nutrition support recovery. Avoid redosing the next day to interrupt the tolerance cycle before it begins.
If phenibut was used to manage social anxiety or emotional distress, reflect on what drove the use. Journaling the experience — what felt better, what felt different, what the cost was — helps identify whether a pattern of self-medication is developing. If use is becoming regular, this is the point to intervene, not after dependence has set in.
Recovery & Support
Phenibut dependence is a recognized medical condition, and withdrawal can be dangerous — do not attempt to stop abruptly after sustained daily use. Medical supervision is strongly recommended for anyone who has been using daily for more than two weeks or at doses exceeding 2–3 g/day.
Baclofen-assisted taper under medical supervision is the most commonly documented approach. The process is gradual and may take weeks to months depending on dose and duration of use. Benzodiazepines or phenobarbital may be added for seizure prevention.
Support resources include addiction medicine specialists, SAMHSA's National Helpline (1-800-662-4357, US), and online communities where people share tapering experiences. If a doctor is unfamiliar with phenibut, directing them to published case reports on phenibut withdrawal management may facilitate appropriate care.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Unresponsiveness, extremely slowed or stopped breathing, inability to be roused, or seizure activity are immediate emergencies. Paradoxical agitation with confusion and psychotic behavior also warrants emergency response. A person who is deeply sedated and cannot be woken should be treated as a medical emergency.
Immediate steps:
- Call emergency services immediately.
- Place the person in the recovery position (on their side) to prevent choking.
- Do not leave them alone. Monitor breathing continuously.
- Do not induce vomiting.
- If an opioid was also taken and naloxone is available, administer it — phenibut itself has no reversal agent, but naloxone can reverse opioid-related respiratory depression.
What to tell the dispatcher: Name the substance (phenibut), the estimated amount and time taken, any other substances involved, and current symptoms. Good Samaritan laws in many jurisdictions protect callers from prosecution when seeking help for a drug-related emergency.
Legal Status[edit]
Phenibut occupies an unusual regulatory position: a licensed prescription medicine in several former Soviet states, an unscheduled or loosely regulated compound in most Western countries, and an increasingly targeted substance as adverse event reports accumulate. It is not currently subject to international scheduling — the WHO Expert Committee on Drug Dependence reviewed phenibut at its 44th meeting (2021) and recommended continued surveillance rather than placement under international control.[14]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States (federal) | Unscheduled; not a dietary ingredient | FDA (2023) determined phenibut does not meet the definition of a dietary ingredient; products sold as supplements are misbranded. Legal to possess. DEA requested public comment on international scheduling (2021)[16][27] |
| United States (state) | Varies by state | Utah: Schedule I (2025). Alabama: Schedule II[17] |
| United Kingdom | Controlled under PSA 2016 | Psychoactive Substances Act 2016 prohibits supply and production. Personal possession not an offense under PSA[17] |
| Australia | Schedule 9 (prohibited) | Classified February 2018 following TGA review due to withdrawal and overdose risk. Importation, sale, and possession without authorization are criminal offenses[15] |
| Canada | Unscheduled | Available online. Health Canada does not classify phenibut as a natural health product. Unregulated[17] |
| Germany | Controlled under NPS Act | Production, possession, and trafficking illegal under New Psychoactive Substances Act[8] |
| France | Prohibited | Not legally available[17] |
| Italy | Controlled substance | Classified as controlled[17] |
| Hungary | Controlled substance | Classified as controlled[17] |
| Lithuania | Prohibited | Banned December 2019[17] |
| Russia, Ukraine, Belarus, Georgia | Licensed prescription medicine | Approved medical use since 1960s. Available as Noofen and other brands[4] |
| Latvia | Licensed prescription medicine | Registered pharmaceutical for anxiety, insomnia, PTSD[4] |
references
- [1]
- [2] ^abcdDambrova M, Zvejniece L, Liepinsh E, Cirule H, Zharkova O, Veinberg G, Kalvinsh I (2008) Comparative pharmacological activity of optical isomers of phenibut — European Journal of Pharmacology doi:10.1016/j.ejphar.2008.01.015
- [3] ^abcdefZvejniece L, Vavers E, Svalbe B, Veinberg G, Rizhanova K, Liepins V, Kalvinsh I, Dambrova M (2015) R-phenibut binds to the alpha2-delta subunit of voltage-dependent calcium channels and exerts gabapentin-like anti-nociceptive effects — Pharmacology, Biochemistry, and Behavior doi:10.1016/j.pbb.2015.07.014
- [4]
- [5]
- [6]